Literature DB >> 22301675

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.

E Lierman, S Smits, J Cools, B Dewaele, M Debiec-Rychter, P Vandenberghe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22301675     DOI： 10.1038/leu.2012.8

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  28 in total

Review 1.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

2.  Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.

Authors:  Arinobu Tojo; Taiichi Kyo; Kazuhito Yamamoto; Hirohisa Nakamae; Naoto Takahashi; Yukio Kobayashi; Tetsuzo Tauchi; Shinichiro Okamoto; Koichi Miyamura; Kiyohiko Hatake; Hiromi Iwasaki; Itaru Matsumura; Noriko Usui; Tomoki Naoe; Meera Tugnait; Narayana I Narasimhan; Stephanie Lustgarten; Heinrich Farin; Frank Haluska; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2017-04-25       Impact factor: 2.490

3.  Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.

Authors:  Yadan Wang; Xiaofei Wu; Jun Deng; Hao Yu; Ren Xu; Zhiyi Zhu; Shichun Tu; Yu Hu
Journal:  Cancer Biol Ther       Date:  2016-08-02       Impact factor: 4.742

Review 4.  Targeted therapy of gastrointestinal stromal tumours.

Authors:  Ashish Jakhetiya; Pankaj Kumar Garg; Gaurav Prakash; Jyoti Sharma; Rambha Pandey; Durgatosh Pandey
Journal:  World J Gastrointest Surg       Date:  2016-05-27

Review 5.  Recent advances in the treatment of gastrointestinal stromal tumors.

Authors:  César Serrano; Suzanne George
Journal:  Ther Adv Med Oncol       Date:  2014-05       Impact factor: 8.168

6.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

Authors:  Andrew Chase; Catherine Bryant; Joannah Score; Nicholas C P Cross
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 7.  Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.

Authors:  Hani J Alturkmani; Ziyan Y Pessetto; Andrew K Godwin
Journal:  Expert Opin Investig Drugs       Date:  2015-06-22       Impact factor: 6.206

8.  Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.

Authors:  Karoline V Gleixner; Barbara Peter; Katharina Blatt; Verena Suppan; Andreas Reiter; Deepti Radia; Emir Hadzijusufovic; Peter Valent
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

Review 9.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 10.  Acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Hyeyoung Lee; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Byung-Sik Cho; Hee-Je Kim
Journal:  Int J Hematol       Date:  2013-04-23       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.